NCT00276172 - Open-Label Natalizumab Safety Extension Study | Biotech Hunter

Enrollment

1,615

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

October 31, 2005

Study Completion Date

January 31, 2006

Conditions

Multiple Sclerosis

Interventions

DRUG

Natalizumab

Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months

Trial Locations (1)

Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in, Cambridge